VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age of 18 and over, male or female                 │ Age of 18 and over, male or female                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with histologically confirmed advanced    │ Patients with histologically confirmed advanced    │     100 │
│ (stage IV) gastric cancer, NSCLC, breast cancer or │ (stage IV) gastric cancer, NSCLC, breast cancer or │         │
│ ovarian cancer, who choose monotherapy of oral     │ ovarian cancer, who choose monotherapy of oral     │         │
│ vascular targeting drug (apatinib) due to          │ vascular targeting drug (apatinib) due to          │         │
│ intolerability or inappropriateness of other       │ intolerability or inappropriateness of other       │         │
│ therapies                                          │ therapies                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Blood pressured controlled at 150/100 mHg          │ Blood pressured controlled at 150/100 mHg          │     100 │
│ following drug administration                      │ following drug administration                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ An ECOG PS score of between 0 and 1                │ An ECOG PS score of between 0 and 1                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A life expectancy of at least 3 months             │ A life expectancy of at least 3 months             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects who volunteer to participate in this      │ Subjects who volunteer to participate in this      │     100 │
│ study and have signed the Informed Consent Form    │ study and have signed the Informed Consent Form    │         │
│ (ICF), with good compliance with treatment and     │ (ICF), with good compliance with treatment and     │         │
│ follow-up                                          │ follow-up                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Confirmed allergy to apatinin and or its           │ Confirmed allergy to apatinin and or its           │     100 │
│ excipients                                         │ excipients                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hypertension (high blood pressure) that can not be │ Hypertension (high blood pressure) that can not be │     100 │
│ controlled by drugs                                │ controlled by drugs                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ A history of active hemorragge, ulcer, intestinal  │ A history of active hemorragge, ulcer, intestinal  │     100 │
│ perforation, intestinal obstruction, or major      │ perforation, intestinal obstruction, or major      │         │
│ surgery no older than 30 days                      │ surgery no older than 30 days                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ NYHA III-IV heart function, or severe hepatic or   │ NYHA III-IV heart function, or severe hepatic or   │     100 │
│ renal insufficiency (Grade 4)                      │ renal insufficiency (Grade 4)                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of multiple factors that affect oral      │ Presence of multiple factors that affect oral      │     100 │
│ medications, such as difficulty swallowing,        │ medications, such as difficulty swallowing,        │         │
│ nausea, vomiting, chronic diarrhea and intestinal  │ nausea, vomiting, chronic diarrhea and intestinal  │         │
│ obstruction                                        │ obstruction                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating women, or women of child-    │ Pregnant or lactating women, or women of child-    │     100 │
│ bearing potential who have planned a pregnancy, or │ bearing potential who have planned a pregnancy, or │         │
│ male and female patients who do not agree to       │ male and female patients who do not agree to       │         │
│ practice adequate contraception during this study  │ practice adequate contraception during this study  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who have a history of psychotropics abuse │ Patients who have a history of psychotropics abuse │     100 │
│ and can not quit, or who have mental disorders     │ and can not quit, or who have mental disorders     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in other drug clinical trial within  │ Participation in other drug clinical trial within  │     100 │
│ the last 4 weeks                                   │ the last 4 weeks                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Prior therapy with VEGFR inhibitors such as        │ Prior therapy with VEGFR inhibitors such as        │     100 │
│ sorafenib and sunitinib                            │ sorafenib and sunitinib                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of comorbidities that seriously affect    │ Presence of comorbidities that seriously affect    │     100 │
│ the patient's safety or ability to complete the    │ the patient's safety or ability to complete the    │         │
│ study, in the investigator's judgment              │ study, in the investigator's judgment              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who can not tolerate apatinib treatment   │ Patients who can not tolerate apatinib treatment   │     100 │
│ as judged by the investigator depending on the     │ as judged by the investigator depending on the     │         │
│ their medical history                              │ their medical history                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients that are considered ineligible for this   │ Patients that are considered ineligible for this   │     100 │
│ study by the investigator                          │ study by the investigator                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Presence of measurable lesions (≥10mm on spiral CT │ Presence of measurable lesions (=10mm on spiral CT │      99 │
│ scan) subject to RECIST 1.1                        │ scan) subject to RECIST 1.1                        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Hemoglobin ≥80g/L; Absolute neutrophil count (ANC) │ Pregnant or lactating women, or women of child-    │      33 │
│ ≥1.5×10\^9/L; Platelets ≥90×10\^9/L; ALT/AST ≤     │ bearing potential who have planned a pregnancy, or │         │
│ 2.5×ULN; or ALT/AST ≤ 5×ULN for patients with      │ male and female patients who do not agree to       │         │
│ hepatic metastases; Serum total bilirubin          │ practice adequate contraception during this study  │         │
│ ≤1.5×ULN; Serum urea nitrogen and creatinine ≤     │                                                    │         │
│ 1.5×ULN; Serum albumin ≥30g/L; Coagulation         │                                                    │         │
│ function (INR≤1.5, APTT≤1.5 ULN)                   │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Age of 18 and over, male or female                 │      39 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Findings of hematology and laboratory tests at the │ Patients who can not tolerate apatinib treatment   │      44 │
│ baseline that meet the following criteria          │ as judged by the investigator depending on the     │         │
│                                                    │ their medical history                              │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 90
Average Levenshtein Ratio of individual lines: 91.5909090909091
OverAll Ratio: 90.79545454545455
